Galvanize Therapeutics, a commercial-stage biomedical platform company operating at the convergence of engineering, biology and healthcare delivery, today announced it has completed a $100 million Series B financing to advance and commercialize its unique AliyaTM Pulsed Electric Field (PEF) energy platform for the treatment of chronic bronchitis symptoms, cardiac arrhythmias, solid tumors, and for drug delivery. Galvanize was created and incubated by the life sciences venture capital firm ATP (Apple Tree Partners), originally as three companies-Gala Therapeutics, Galaxy Medical, and Galvanize Therapeutics-that recently merged into one company under the Galvanize Therapeutics name. The funding round was led by Fidelity Management & Research Company with participation by Intuitive Surgical, ATP, and Gilmartin Capital.

Galvanize Therapeutics aims to become the global leader in delivering medical technology innovations that drive biologic processes to treat a range of diseases, starting with treating chronic bronchitis symptoms, cardiac arrhythmias, and solid tumors. Formed by ATP (Apple Tree Partners) in 2022, Galvanize has its headquarters in San Carlos, Calif., and is researching and commercializing its revolutionary AliyaTM Pulsed Electric Field (PEF) energy platform in the United States and Europe.